Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57,596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Chanan-Khan A, et al. Among authors: lee k. Leuk Lymphoma. 2009 Jul;50(7):1096-101. doi: 10.1080/10428190902912460. Leuk Lymphoma. 2009. PMID: 19479618 Clinical Trial.
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. Sher T, et al. Among authors: lee k. Br J Haematol. 2011 Jul;154(1):104-10. doi: 10.1111/j.1365-2141.2011.08703.x. Epub 2011 May 9. Br J Haematol. 2011. PMID: 21554260 Free PMC article. Clinical Trial.
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Chanan-Khan AA, et al. Among authors: lee k. Br J Haematol. 2011 Nov;155(4):457-67. doi: 10.1111/j.1365-2141.2011.08882.x. Epub 2011 Oct 20. Br J Haematol. 2011. PMID: 22010965 Free PMC article. Clinical Trial.
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Masood A, et al. Among authors: lee kp. Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15. Br J Haematol. 2012. PMID: 22171982 Free article. Clinical Trial.
Development of target-specific treatments in multiple myeloma.
Chanan-Khan AA, Borrello I, Lee KP, Reece DE. Chanan-Khan AA, et al. Br J Haematol. 2010 Oct;151(1):3-15. doi: 10.1111/j.1365-2141.2010.08262.x. Epub 2010 Jul 7. Br J Haematol. 2010. PMID: 20618339 Free PMC article. Review.
57,596 results
You have reached the last available page of results. Please see the User Guide for more information.